NO155290C - Analogifremgangsmaate til fremstilling av terapeutisk virksomme sulfonylurinstoffderivater. - Google Patents

Analogifremgangsmaate til fremstilling av terapeutisk virksomme sulfonylurinstoffderivater.

Info

Publication number
NO155290C
NO155290C NO803855A NO803855A NO155290C NO 155290 C NO155290 C NO 155290C NO 803855 A NO803855 A NO 803855A NO 803855 A NO803855 A NO 803855A NO 155290 C NO155290 C NO 155290C
Authority
NO
Norway
Prior art keywords
sulphonylurine
ingredients
preparation
therapeutically effective
analogue procedure
Prior art date
Application number
NO803855A
Other languages
English (en)
Norwegian (no)
Other versions
NO803855L (no
NO155290B (no
Inventor
Rudi Weyer
Volker Hitzel
Karl Geisen
Guenter Regitz
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO803855L publication Critical patent/NO803855L/no
Publication of NO155290B publication Critical patent/NO155290B/no
Publication of NO155290C publication Critical patent/NO155290C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO803855A 1979-12-19 1980-12-18 Analogifremgangsmaate til fremstilling av terapeutisk virksomme sulfonylurinstoffderivater. NO155290C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19792951135 DE2951135A1 (de) 1979-12-19 1979-12-19 Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung

Publications (3)

Publication Number Publication Date
NO803855L NO803855L (no) 1981-06-22
NO155290B NO155290B (no) 1986-12-01
NO155290C true NO155290C (no) 1987-03-11

Family

ID=6088937

Family Applications (2)

Application Number Title Priority Date Filing Date
NO803855A NO155290C (no) 1979-12-19 1980-12-18 Analogifremgangsmaate til fremstilling av terapeutisk virksomme sulfonylurinstoffderivater.
NO1996009C NO1996009I1 (no) 1979-12-19 1996-07-30 Glimepiride

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1996009C NO1996009I1 (no) 1979-12-19 1996-07-30 Glimepiride

Country Status (21)

Country Link
US (1) US4379785A (es)
EP (1) EP0031058B1 (es)
JP (1) JPS56108762A (es)
AR (3) AR230989A1 (es)
AT (1) ATE6934T1 (es)
AU (1) AU538129B2 (es)
CA (1) CA1167033A (es)
DE (2) DE2951135A1 (es)
DK (1) DK156434C (es)
ES (6) ES8200665A1 (es)
FI (1) FI75338C (es)
GR (1) GR72534B (es)
HU (1) HU184943B (es)
IE (1) IE50635B1 (es)
IL (1) IL61733A (es)
LU (1) LU90244I2 (es)
MX (4) MX174496B (es)
NL (1) NL950026I2 (es)
NO (2) NO155290C (es)
PT (1) PT72226B (es)
ZA (1) ZA807911B (es)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US4985417A (en) * 1989-05-02 1991-01-15 Trager Seymour F Treatment of glaucoma
JP3465247B2 (ja) * 1992-12-28 2003-11-10 アベンティス ファーマ株式会社 動脈硬化症の予防および治療剤
DE4344957A1 (de) * 1993-12-30 1995-07-06 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen
US5631275A (en) * 1993-12-30 1997-05-20 Hoechst Aktiengesellschaft Substituted benzenesulfonylureas and -thioureas, preparation processes and possible uses of pharmaceutical preparations based on these compounds
ID26082A (id) 1998-03-19 2000-11-23 Briston Myers Squib Company Sistem pengiriman lepas terkendali dwifasa untuk zat-zat farmasi kelarutan tinggi dan metodenya
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
MXPA03001157A (es) * 2000-08-07 2004-02-17 Ranbaxy Signature Llc Formulacion liquida de metformina.
AR033390A1 (es) 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US6806381B2 (en) * 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
AU2003235814A1 (en) * 2002-01-07 2003-07-24 Sun Pharmaceutical Industries Limited Novel process for the preparation of trans-3- ethyl-2,5- dihydro-4- methyl-n-(2-( 4-(((((4-methyl cyclohexyl) amino)carbonyl) amino)sulfonyl) phenyl)ethyl) -2-oxo-1h-pyrrole -1-carboxamide
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US20040176425A1 (en) * 2003-01-24 2004-09-09 Washburn William N. Cycloalkyl containing anilide ligands for the thyroid receptor
CZ2003530A3 (cs) * 2003-02-21 2004-07-14 Zentiva, A.S. Způsob výroby glimepiridu a příslušný meziprodukt
US7459474B2 (en) * 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
KR100712234B1 (ko) * 2003-08-08 2007-04-27 명문제약주식회사 글리메피라이드의 제조방법
DK1675625T3 (da) 2003-09-17 2013-05-13 Univ Texas Mekanisme-baseret målrettet pancreatisk beta-celle-afbildning
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AR046778A1 (es) 2003-11-12 2005-12-21 Phenomix Corp Compuestos heterociclicos de acido boronico. metodos de obtencion y composiciones farmaceuticas.
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
CA2573848A1 (en) * 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7361766B2 (en) 2005-01-12 2008-04-22 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7368458B2 (en) * 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076598A2 (en) * 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2006078697A1 (en) * 2005-01-18 2006-07-27 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006086464A2 (en) * 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
EP1700848A1 (en) * 2005-03-11 2006-09-13 IPCA Laboratories Limited Method for the Manufacture of Compounds Related to the Class of Substituted Sulphonyl Urea Anti-Diabetics
AU2005329763A1 (en) * 2005-04-01 2006-10-05 Usv Limited A novel process for preparation of substantially pure Glimepiride
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US20060287342A1 (en) * 2005-06-17 2006-12-21 Mikkilineni Amarendra B Triazolopyrimidine heterocycles as cannabinoid receptor modulators
US7317012B2 (en) * 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7572808B2 (en) * 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en) * 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7629342B2 (en) * 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7452892B2 (en) * 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
MX2008000811A (es) * 2005-07-28 2008-03-18 Squibb Bristol Myers Co Tetrahidro-1h-pitido[4,3-b]indoles substituidos como agonistas y antagonistas del receptor de serotonina.
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) * 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
CN101092402B (zh) * 2006-06-23 2012-02-08 唐仲雄 磺酰脲类化合物及其医药用途
EP2089355A2 (en) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
EP2099767A1 (en) 2006-11-01 2009-09-16 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20090011994A1 (en) * 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
US20090076125A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched glimepiride
JP2011503081A (ja) 2007-11-01 2011-01-27 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１および／またはＮＦ−κＢ活性の調節剤として有用な非ステロイド性化合物、並びにその使用
PE20091928A1 (es) * 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
NZ594024A (en) * 2009-02-13 2013-08-30 Boehringer Ingelheim Int Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
UY32441A (es) 2009-02-13 2010-09-30 Boehringer Ingelheim Int Composicion farmaceutica, metodos de tratamiento y sus usos
CN102448456A (zh) 2009-03-27 2012-05-09 百时美施贵宝公司 用dpp-iv抑制剂预防重度有害心血管事件的方法
ES2430088T3 (es) 2009-05-15 2013-11-18 Novartis Ag Derivados de benzoxazolona como inhibidores de aldosterona sintasa
PE20120403A1 (es) 2009-05-15 2012-05-03 Novartis Ag Aril-piridinas como inhibidoras de sintasa de aldosterona
UY32662A (es) 2009-05-28 2010-12-31 Novartis Ag Derivados amino-propionicos sustituidos como inhibidores de neprilisina
WO2010136474A2 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
CA2775961C (en) 2009-09-30 2017-11-07 Boehringer Ingelheim International Gmbh Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
WO2011039108A2 (en) 2009-09-30 2011-04-07 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
EP2993169B1 (en) 2009-11-17 2017-12-20 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2507234B1 (en) 2009-11-30 2014-03-12 Novartis AG Imidazole derivatives as aldosterone synthase inhibitors
BR112013000626B1 (pt) 2010-07-09 2019-11-26 Bhv Pharma Inc formulação farmacêutica e método para preparar uma forma de dosagem da mesma
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
TR201101809A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
EP2779999A2 (en) 2011-11-15 2014-09-24 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising atorvastatin and glimepiride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2892896B1 (en) 2012-09-05 2016-06-29 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
EP2892897A1 (en) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9163040B2 (en) 2013-02-14 2015-10-20 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2968245B1 (en) 2013-03-15 2021-05-05 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
DK2986304T3 (da) 2013-04-18 2022-04-04 Boehringer Ingelheim Int Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
CN103288703B (zh) * 2013-06-09 2015-10-21 南通市华峰化工有限责任公司 Ⅱ型糖尿病药物格列美脲中间体苯磺酰胺的合成方法
CN103420891B (zh) * 2013-06-09 2015-10-21 南通市华峰化工有限责任公司 Ⅱ型糖尿病药物格列美脲中间体苯磺胺三光气的合成方法
MX2016001020A (es) 2013-07-25 2016-08-03 Novartis Ag Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca.
CA2918077A1 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
EP2992876A1 (en) 2014-09-05 2016-03-09 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of sitagliptin
EP3009422A1 (en) * 2014-10-14 2016-04-20 Ludwig-Maximilians-Universität München Photo-switchable sulfonylureas and their uses
BR112017014194A2 (pt) 2015-01-23 2018-01-09 Novartis Ag conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN108383768A (zh) * 2018-04-13 2018-08-10 江西博雅欣和制药有限公司 一种格列美脲原料药合成工艺
CN112028807A (zh) * 2020-08-07 2020-12-04 重庆康刻尔制药股份有限公司 一种格列美脲原料药的精制方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670700U (de) 1952-11-12 1954-01-21 Siemens Ag Aufhaengevorrichtung fuer pendelleuchten.
DE1198354B (de) * 1963-09-25 1965-08-12 Hoechst Ag Verfahren zur Herstellung von Benzol-sulfonylharnstoffen
LU47776A1 (es) * 1964-07-30 1966-07-13
DE1445774A1 (de) * 1964-07-30 1969-01-23 Hoechst Ag Verfahren zur Herstellung von Benzolsulfonylharnstoffen
DE1443911C3 (de) * 1964-12-08 1974-12-05 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt Benzolsulfonylharnstoffe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
DE1670700B2 (de) * 1966-05-14 1978-06-22 Hoechst Ag, 6000 Frankfurt Benzolsulfonylharnstoffe, Verfahren zu ihrer Herstellung und deren Verwendung
US3646009A (en) * 1967-03-15 1972-02-29 Boehringer & Soehne Gmbh Anti-diabetically active sulfonyl-semicarbazides
US3819633A (en) * 1970-04-01 1974-06-25 Erba Carlo Spa (iso)quinolyl sulfonylureas having antidiabetic activity
US3962244A (en) * 1971-01-23 1976-06-08 Hoechst Aktiengesellschaft Benzene sulfonyl ureas
DE2103118A1 (en) * 1971-01-23 1972-08-24 Farbwerke Hoechst AG, vormals Meister Lucius & Brüning, 6000 Frankfurt 4 (2-heterocyclylethyl) - benzenesulphonylureas - with hypoglycaemic activity
DE2238870C3 (de) * 1972-08-07 1978-09-28 Hoechst Ag, 6000 Frankfurt Benzolsulfonylharnstoffe
DE2621958A1 (de) * 1976-05-18 1977-12-08 Hoechst Ag Benzolsulfonylharnstoffe und verfahren zu ihrer herstellung
MTP848B (en) * 1978-06-27 1980-06-24 Hoechst Ag Sulfonyl ureas process for their manufacture pharmaceutical preparation on the basis of there compounds and their use

Also Published As

Publication number Publication date
MX8352A (es) 1993-11-01
DE2951135A1 (de) 1981-06-25
NL950026I1 (es) 1996-01-02
ES498224A0 (es) 1982-02-01
HU184943B (en) 1984-11-28
DK540280A (da) 1981-06-20
IE50635B1 (en) 1986-05-28
PT72226A (de) 1981-01-01
ES498225A0 (es) 1982-03-01
NO1996009I1 (no) 1996-07-30
JPH0139424B2 (es) 1989-08-21
JPS56108762A (en) 1981-08-28
GR72534B (es) 1983-11-17
ES8202543A1 (es) 1982-02-01
EP0031058B1 (de) 1984-04-04
ES498228A0 (es) 1982-02-01
AR230989A1 (es) 1984-08-31
CA1167033A (en) 1984-05-08
IL61733A0 (en) 1981-01-30
FI803937L (fi) 1981-06-20
ES8202542A1 (es) 1982-02-01
IE802676L (en) 1981-06-19
ES8202541A1 (es) 1982-02-01
MX174496B (es) 1994-05-19
DE3067390D1 (en) 1984-05-10
ES497661A0 (es) 1981-11-01
AR231131A1 (es) 1984-09-28
US4379785A (en) 1983-04-12
AR240922A1 (es) 1991-03-27
AU6552380A (en) 1981-06-25
ES498226A0 (es) 1982-03-01
AU538129B2 (en) 1984-08-02
DK156434B (da) 1989-08-21
NO803855L (no) 1981-06-22
NO155290B (no) 1986-12-01
NL950026I2 (nl) 1997-01-06
MX8254A (es) 1993-04-01
LU90244I2 (fr) 1998-07-20
ES8202799A1 (es) 1982-03-01
ES8202798A1 (es) 1982-03-01
PT72226B (de) 1982-03-26
FI75338B (fi) 1988-02-29
IL61733A (en) 1985-05-31
ZA807911B (en) 1981-12-30
FI75338C (fi) 1988-06-09
EP0031058A1 (de) 1981-07-01
ATE6934T1 (de) 1984-04-15
AR240922A2 (es) 1991-03-27
ES498227A0 (es) 1982-02-01
DK156434C (da) 1990-01-22
ES8200665A1 (es) 1981-11-01
MX6926E (es) 1986-12-01

Similar Documents

Publication Publication Date Title
NO155290C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme sulfonylurinstoffderivater.
NO154058C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-heterocyklyl-4-piperidinaminer.
NO155774C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazo-diazepin-derivater.
NO151362C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive urinstoffderivater.
NO146909C (no) Fremgangsmaate til fremstilling av terapeutisk virksomme pyrrolidinderivater.
NO150760C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminotiazoler.
NO142034C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenoletere.
NO158679C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 2-penem-3-karboksylsyreforbindelser.
NO149389C (no) Fremgangsmaate til fremstilling av 4,1`,6`-triklor-4,1`,6`-trideoksy-galaktosukrose
NO794069L (no) Fremgangsmaate ved fremstilling av terapeutisk virksomme imidayolderivater.
NO812344L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive steroider.
NO157861C (no) Analogifremgangsmaate til fremstilling av aminopyridaziner.
NO154492C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme forbindelser.
NO152649C (no) Analogifremgangsmaate for fremstilling av farmasoeytisk aktive fenylalkylaminer.
NO163775C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isoindolinyl-alkyl-piperaziner.
NO781878L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridobenzodiazepiner.
NO148644C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive sukkerderivater.
NO151288C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indolokinolizindiner
NO781879L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridobenzodiazepiner
NO152787C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive fenyl-kinolizidiner.
NO153853C (no) Fremgangsmaate for fremstilling av 17beta-hydroksy-17alfa-pregn-5-en-21-karboksylsyre-gamma-laktoner.
NO801142L (no) Fremgangsmaate til fremstilling av klordioksyd.
NO791458L (no) Fremgangsmaate til fremstilling av 1,2-dikloretan
NO152843C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimidopyrimidiner.
NO160203C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme fenotiazin-forbindelser.

Legal Events

Date Code Title Description
MK1K Patent expired

Free format text: EXPIRED IN DECEMBER 2000